Can decision analytic modelling promote clinical translation of personalised medicine markers for oncology drugs?

决策分析模型能否促进肿瘤药物个性化医学标志物的临床转化？

• 批准号: nhmrc : 1028492
• 负责人: A/Pr Michael Coory
• 金额: $ 4.66万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/decision-analytic-modelling-oncology-drugs/110640
• 关键词: decision; analytic; modelling; promote; clinical

Personalised medicine is an approach that has great potential to improve healthcare. There has been limited success to date, however, in utilising proposed tests in the clinical. It is proposed that use of mathematical models early in the development of personalised medicine tests will allow early understanding of the value that the test will have for patients and society. Such insight will help build a strong case to undertake the research required before personalised medicine can be more widely used to improve treatment for cancer.

个性化医疗是一种有巨大潜力改善医疗保健的方法。然而，到目前为止，在将拟议的测试应用于临床方面取得的成功有限。有人建议，在开发个性化药物测试的早期使用数学模型，将使人们能够及早了解该测试对患者和社会的价值。这种洞察力将有助于建立一个强有力的案例，在个性化药物能够更广泛地用于改善癌症治疗之前，进行所需的研究。